Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Gastroenterology · Gastroenterology · 2026-11-01
Guideline
Levy et al. AGA/AASLD Clinical Practice Guideline on Management of Primary Biliary CholangitisGastroenterology · Lancet · 2026-09-30
RCTn = 880
Goel et al. 8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in IndiaGastroenterology · Lancet Gastroenterol Hepatol · 2026-09-23
RCTn = 428
Yaqub et al. Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trialGastroenterology · Lancet Gastroenterol Hepatol · 2026-08-26
RCTn = 102
Loomba et al. ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trialGastroenterology · Lancet Gastroenterol Hepatol · 2026-08-25
RCTn = 342
Kudo et al. On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial